Roche and TIB Molbiolb partners to extend its PCR-test portfolio in the battle against new infectious illnesses

0 77

TIB Molbiol specialises at developing ultra-fast assays for emerging infectious diseases, as evidenced by the COVID-19 pandemic.

Roche will be able to increase its range of over 45 CE-IVD tests and more than 100 research use assays on its LightCycler PCR instruments as a result of the acquisition.

TIB Molbiol will continue to focus on the research and development of assays that address key healthcare needs, such as biological threats, in a timely manner.

Roche said on Wednesday that it has finalised its share purchase agreement to acquire 100 percent of TIB Molbiol Group’s outstanding shares. The Diagnostics division will continue to run TIB Molbiol as a subsidiary. Roche and TIB Molbiol will combine their resources to create quick diagnostics for new pathogens and future health hazards such as infectious illnesses.

“I am very pleased that together with TIB Molbiol, we can significantly improve access for patients to a broader spectrum of diagnostic tests – from high volume routine tests to the diagnosis of rare diseases. TIB Molbiol will continue to be an innovation engine and frontrunner in our common fight against infectious diseases, such as SARS-CoV-2. TIB Molbiol has helped to shape the future of PCR infectious disease testing, and will continue to drive cutting-edge research so we can bring better healthcare outcomes to patients faster,”

said Thomas Schinecker, CEO Roche Diagnostics.

With the addition of over 45 CE-IVD assays and over 100 research use only assays to the Roche family, patients throughout the world will have faster access to even more clinically essential diagnostic tests. Roche’s molecular diagnostics solutions will be expanded by TIB Molbiol, particularly for the LightCycler PCR and MagNA Pure sample preparation systems, which are open platforms.

SARS, anthrax, avian influenza virus H5N1, MERS, the new influenza virus H1N1 swine, Ebola virus, Zika virus, and, most recently, SARS-CoV-2 virus and its variants are among the biological threats to whom the two companies have partnered for more than 20 years. For example, TIB Molbiol demonstrated their ability to build PCR tests for the identification of novel infections within days in 2001 with anthrax and 2003 with SARS-CoV1.

Leave A Reply

Your email address will not be published.